AGM Statement

RNS Number : 2462T
Advanced Medical Solutions Grp PLC
03 June 2009



For immediate release

June 2009

Advanced Medical Solutions Group plc 

(“AMS” or “the Company”)

Annual General Meeting

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, will hold its Annual General Meeting in Tarporley, Cheshire at 11.00am this morningDr Geoffrey Vernon, the Company’s Chairman, will make the following comments on current trading:

“I am pleased to advise that AMS remains well positioned to exploit significant growth opportunities in its core markets.

“Organic growth is set to continue this year:

  • LiquiBand™ approvals and multi-partner US market entry expected during H2

  • Silver dressings market continues to expand

  • ActivHeal® value proposition remains attractive to NHS Trusts

  • Publication of positive multi-centre clinical data, expected during H2, should boost demand 
    for InteguSeal* in 2010

The difficult global economic conditions are affecting our partners and we expect to see a significant effect on halfyear phasing with a higher than normal second half loading this year.

However, given the exciting, imminent product launches and market entry opportunitiesthe Board remains confident in the outlook for the 2009 full year.”

For further information, please contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

www.admedsol.com

 Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Richard Jones/Tim Pratelli

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 


This information is provided by RNS
The company news service from the London Stock Exchange

END

AGMSSIFMESUSELM